This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1799-1802, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1799-1802.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Resistance Studies with Daptomycin

Jared A. Silverman,* Nicole Oliver, Ted Andrew, and Tongchuan Li

Cubist Pharmaceuticals, Inc., Cambridge, Massachusetts 02139

Received 8 August 2000/Returned for modification 16 October 2000/Accepted 12 March 2001


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

We studied the in vitro emergence of resistance to daptomycin using three methods: spontaneous resistance incidence, serial passage in the presence of increasing drug concentrations, and chemical mutagenesis. No spontaneously resistant mutants were obtained for any organism tested (<10-10 for Staphylococcus aureus, <10-9 for Staphylococcus epidermidis, <10-9 for Enterococcus faecalis, <10-9 for Enterococcus faecium, <10-8 for Streptococcus pneumoniae). Population analysis demonstrated that bacterial susceptibility to daptomycin is heterogeneous. Assay results were sensitive to calcium concentration and culture density, both of which can affect apparent resistance rates. Stable S. aureus mutants were isolated by both serial passage in liquid media and chemical mutagenesis. The daptomycin MICs for these isolates were 8- to 32-fold higher than for the parental strain. Many mutants with high MICs (>12.5 µg/ml) had significant growth defects but did not display phenotypes typical of S. aureus small colony variants. The voltage component (Delta psi ) of the bacterial membrane potential was increased in three independent resistant isolates. In vivo data showed that some daptomycin-resistant mutants had lost significant virulence. For other mutants, the degree of in vitro resistance was greater than the change in in vivo susceptibility. These results suggest that infection with some daptomycin-resistant organisms may still be easily treatable.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Daptomycin is a novel lipopeptide antibiotic with potent bactericidal activity in vitro against most clinically important gram-positive pathogens, including vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, coagulase-negative staphylococci, and penicillin-resistant Streptococcus pneumoniae (12, 19, 25, 26, 28). The mechanism of action, while not yet fully elucidated, appears to involve disruption of bacterial plasma membrane function (1-5). Daptomycin was efficacious in phase 2 clinical trials in skin and soft tissue infection and bacteremia (28). Additional phase 2 and 3 clinical studies are ongoing.

Results from in vitro studies and clinical trials indicate that resistance to daptomycin is rare (16, 28; P. Courvalin, personal communication; G. W. Kaatz, personal communication). However, one group has reported relatively high resistance rates in vitro (18). In an effort to resolve this discrepancy, we determined spontaneous resistance rates and analyzed technical factors influencing those rates. In addition, the possible utility of resistant mutants in pinpointing daptomycin's mechanism of action prompted us to isolate and analyze resistant organisms.

(Portions of this work were presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy [N. Oliver, T. Andrew, T. Li, and J. Silverman, poster F-117], San Diego, Calif., 24 to 27 September 1998.)


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Strains, media, and antibiotics. Bacteria were propagated at 37°C. Staphylococci were grown in Mueller-Hinton broth (MHB; Becton, Dickinson, Cockeysville, Md.), enterococci in brain heart infusion (Becton, Dickinson), and S. pneumoniae in Todd-Hewitt broth plus 5% horse serum. MIC testing was performed according to NCCLS guidelines for broth microdilution (23) except that all cultures were grown at 37°C. In addition, daptomycin MICs were determined using MHB supplemented with 50 mg of Ca2+ per liter (MHBc). Modifications for determining nisin MICs were made as previously described (27). Vancomycin, ampicillin, gentamicin, and nisin were purchased from Sigma Chemical Company (St. Louis, Mo.). Complete defined media was obtained from JRH Biosciences (Lenexa, Kans.).

Heterogeneity assay. Heterogeneous susceptibility was measured based on methods developed by de Lencastre et al. (8). Overnight cultures were plated at dilutions (made in MHBc) ranging from 100 to 10-7 on Mueller-Hinton agar (MHA) or MHA plus 50 mg of CaCl2 per liter containing twofold dilutions of daptomycin over the range 0.125 to 64 µg/ml.

Serial-passage mutagenesis. On day 1, MHBc containing daptomycin at 0.25, 0.5, 1, or 2 times the MIC was inoculated with S. aureus (strain Sa42) from a single colony. Cultures were incubated overnight at 37°C with shaking. From the highest concentration that supported growth, cultures were diluted 1:10,000 into fresh media plus daptomycin at twofold dilutions. This process was continued for 21 days or until three successive cultures failed to show any decrease in susceptibility. Putative mutants were colony purified for three generations on MHA, prior to further characterization.

Chemical mutagenesis. N-Methyl-N'-nitro-N-nitrosoguanidine (MNNG; Sigma) mutagenesis was performed using methods developed by Miller (21) and Chatterjee (7). Mid-exponential cultures of S. aureus (ca. 3 × 108/ml) were washed twice with 0.03 M phosphate buffer (pH 7.0) and resuspended in 0.05 M Tris-acetate (pH 6.0)-10 mM MgCl2 (TAM). Then, 50 µg of MNNG per ml was added, and cells were incubated at 37°C to achieve 50% killing (30 min). Bacteria were washed three times with TAM, incubated overnight at 37°C in MHBc, and plated on selective media for 48 h. Putative mutants were purified on MHA prior to further characterization. To ensure that all mutants were independent, only one mutant was isolated from each selection plate.

Virulence titration and daptomycin protection studies. For virulence titrations, five CD-1 female mice per group (Charles River Laboratories, Wilmington, Mass.) were inoculated intraperitoneally (i.p.) with 10-fold dilutions ranging from 105 to 108 CFU in phosphate-buffered saline (PBS) containing 6% hog gastric mucin (Sigma) or PBS-mucin only. The 50 and 100% lethal doses (LD50 and LD100) were calculated based on the number of mice surviving after 7 days. For daptomycin protection studies, mice were inoculated i.p. with two times the LD100. Daptomycin was dissolved in PBS and administered subcutaneously immediately and at 4 h postinfection. The 50% protective dose (PD50) was calculated via the method of probits (9) from the number of mice surviving after 7 days.

Membrane potential measurements. Accumulation of the membrane-permeant anion tetraphenyl phosphonium bromide (TPP) was used to measure the voltage component of the bacterial membrane potential (Delta psi ) (15, 17, 20). Overnight cultures of S. aureus were diluted 1:1,000 into fresh MHBc, grown for 2 h at 37°C, and then shifted to room temperature and grown for an additional 2 h. Samples were collected for protein determination via the Coomassie protein assay (Pierce Chemical, Rockford, Ill.). Four 4-ml aliquots were withdrawn from the remaining culture. One was treated with 8% butanol for 10 min prior to labeling to produce a background value. Cells were labeled with 10 µM [3H]TPP (29 Ci/mmol; Moravek Biochemicals, Brea, Calif.) for 10 min, then filtered through GF/C filters (Whatman, Mardstone, United Kingdom). Filters were washed with 0.15 M NaCl and dried; the radioactivity was determined in a liquid scintillation counter. The Nernst equation, Delta psi  = [-(RT/F)ln([TPP+]in/[TPP+]out)], and a 4.2-µl intracellular volume per mg of protein (determined as previously described [24]) were used to calculate Delta psi .


    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

Spontaneous resistance testing. Previous studies of daptomycin resistance have yielded conflicting results, with rates varying by up to 3 orders of magnitude for some species (16, 18, G. W. Kaatz, personal communication; P. Courvalin, personal communication; protocol summary report no. B8B FP 2001 [Lilly Research Laboratories, Greenfield, Ind. 1986]) To resolve this discrepancy, we carried out additional resistance studies. Initially, we isolated colonies on MHA containing daptomycin at concentrations above the MIC. However, these isolates were not resistant. They failed to grow when restreaked to MHA containing daptomycin and, following purification on MHA, yielded MICs identical to those for the parent strain. The appearance of these colonies indicates that susceptibility to daptomycin is heterogeneous, as has been described for methicillin and vancomycin (6, 13, 14). This is demonstrated in Fig. 1A. Population heterogeneity may contribute to differences in apparent resistance rates.


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1.   Susceptibility to daptomycin is heterogeneous in S. aureus. (A) Susceptibility is heterogeneous in both laboratory (Sa42) and clinical (Sa675) isolates (, Sa42; open circle , Sa675). Data are mean values ± the standard deviation. (B) Heterogeneous susceptibility in Sa42 is affected by calcium (open circle , MHA [MIC = 1 µg/ml]; , MHA plus 50 mg of Ca2+ per liter [MIC = 0.3 µg/ml]). Data are mean values ± the standard deviation. (C) Heterogeneous susceptibility is observed in daptomycin-resistant mutants (, Sa42 [parent]; , Sa278 [class 1]; open circle , Sa295 [class 2]; , Sa291 [class 3]). Representative data are shown.

Experimental factors that increase population heterogeneity could increase apparent resistance rates. The activity of daptomycin is calcium dependent (10), and the levels of free calcium in MHA are variable (23). We determined the effect of calcium levels on population heterogeneity. As shown in Fig. 1B, the addition of 1 mM CaCl2 to the test agar results in homogeneous susceptibility and eliminates the appearance of falsely resistant colonies. Differences in calcium levels may have contributed to past differences in spontaneous resistance rates. Consistent with this idea, it has previously been demonstrated that resistance rates in liquid media increase as calcium levels decrease (29).

Based on the studies described above, we performed all resistance testing by plating overnight cultures on MHA supplemented with 1 mM CaCl2 and daptomycin at 8 times the MIC. Eight laboratory (American Type Culture Collection, Rockville, Md.) and eight clinical isolates (provided by D. Snydman, New England Medical Center, Boston, Mass.) were tested. No spontaneously resistant mutants were obtained, yielding resistance rates of <10-10 for S. aureus (n = 4 strains tested), <10-9 for Staphylococcus epidermidis (n = 4), <10-9 for Enterococcus faecalis (n = 4), <10-9 for E. faecium (n = 2), and <10-9 for S. pneumoniae (n = 2). These values support earlier reports of low resistance rates (16; G. W. Kaatz, personal communication; P. Courvalin, personal communication). As described above, earlier reports of higher rates of spontaneous resistance (18) may reflect variations in calcium levels in the test media and the effects of population heterogeneity.

Serial passage and chemical mutagenesis. Two methodologies were employed to obtain daptomycin-resistant S. aureus. One mutant (Sa278) was obtained via 21-day serial passage in liquid culture. (Pulsed-field gel electrophoresis fingerprinting confirms that Sa278 is a derivative of the parent strain [data not shown]). Eleven additional independent mutants (Sa284 to Sa293 and Sa295) with varied colony morphology, growth phenotypes, and antibiotic resistance were isolated via chemical mutagenesis. The phenotypes of all mutants are summarized in Table 1. MIC increases were relatively modest (8- to 32-fold), consistent with the findings of previous serial passage experiments (18, 22). Daptomycin resistance is stable during repeated passage in the absence of continued drug selection (data not shown).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Growth phenotypes and MICs of mutants obtained via serial passage or chemical mutagenesisa

Mutants were grouped into three classes based on their growth phenotypes and antibiotic susceptibility (n >=  3 for all values). Class 1 mutants (including Sa278) exhibited normal growth rates and were cross-resistant to the peptide antibiotic nisin. Class 2 mutants had reduced growth rates on MHA, poor or no growth in complete defined media (CDM), and no antibiotic cross-resistance. Class 3 mutants showed severe growth defects in MHB and CDM, poor or no pigmentation on MHA, and no antibiotic cross-resistance. Poorly growing mutants (classes 2 and 3) were not rescued by the addition of menadione, hemin, and thiamine to MHA and were susceptible to gentamicin, suggesting that they were not classic S. aureus small colony variants. All classes of mutants retained the heterogeneous susceptibility of the parental strain (Fig. 1C) and exhibited homogeneous susceptibility in the presence of 1 mM Ca2+ (data not shown). Daptomycin remained bactericidal at 8 times the MIC against all classes of mutants (data not shown). None of the mutants demonstrated cross-resistance to vancomycin or ampicillin, a finding consistent with known differences in the mechanism of action of these drugs.

In vivo studies. Selected mutants were tested for virulence in an acute murine IP infection model (Table 2). Sa278 and its daptomycin-sensitive parent had comparable LD50 values, consistent with similar growth rates in vitro. The PD50 for the resistant strain was <5-fold higher than that of the parent. This contrasts with a 16-fold increase in daptomycin MIC for Sa278 (verified by repeated testing [n = 40]) and suggests that some in vitro resistant strains will still be susceptible in vivo. The LD50 for a class 2 mutant was >20-fold higher (i.e., no animals died at the highest innoculum tested), meaning that a PD50 could not be determined. This loss of virulence may be a consequence of the growth defects observed in vitro; alternatively, this strain may be defective in the production of critical virulence factors. Whether these defects are a consequence of the acquisition of daptomycin resistance remains to be determined.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   MIC, LD50, and PD50 values for selected strainsa

Membrane potential. Daptomycin's mechanism of action is not clearly defined. Earlier research has suggested two likely targets: dissipation of the bacterial membrane potential (1) and inhibition of lipoteichoic acid synthesis (4, 5). We measured the membrane potential in the wild type and in selected class 1 mutants via the uptake of the permeant anion tetraphenyl phosphonium. As shown in Table 3, the voltage difference across the cytoplasmic membrane of daptomycin-resistant mutants is increased compared to the parent strain. This may be consistent with the membrane potential as the primary target. Higher levels of daptomycin may be necessary to fully dissipate the membrane potential in these mutants, accounting for their higher MICs. This may also account for their cross-resistance to nisin, which is known to dissipate membrane potential.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Delta psi in class 1 mutantsa

Conclusion. Antibiotic resistance is a growing worldwide problem, requiring the development of novel agents to combat resistant organisms. The low spontaneous resistance rates, limited increases in MICs during serial passage, and ease of treatment of resistant isolates are encouraging for the clinical development of daptomycin. The low resistance potential in vitro may provide daptomycin with a low clinical resistance rate, prolonging the drug's utility. The higher resistance rates in one earlier report may be attributable to variances in experimental protocols. Preliminary analysis of resistant mutants supports alteration of membrane potential as a mechanism of action for daptomycin.


    ACKNOWLEDGMENTS

We thank Jeff Alder, Frank Tally, and Grace Thorne for their helpful discussions. We are grateful to Glenn Kaatz for the gift of Sa675 and for making the initial observation of heterogeneous susceptibility to daptomycin.


    FOOTNOTES

* Corresponding author. Mailing address: Cubist Pharmaceuticals, Inc., 24 Emily St., Cambridge, MA 02139. Phone: (617) 576-4190. Fax: (617) 576-0232. E-mail: jsilverm{at}cubist.com.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References

1. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287[Abstract/Free Full Text].
2. Allen, N. E., W. E. Alborn, Jr., and J. N. Hobbs, Jr. 1991. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. 35:2639-2642[Abstract/Free Full Text].
3. Boaretti, M., and P. Canepari. 1995. Identification of daptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob. Agents Chemother. 39:2068-2072[Abstract].
4. Boaretti, M., P. Canepari, M. del Mar Lleò, and G. Satta. 1993. The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J. Antimicrob. Chemother. 31:227-235[Abstract/Free Full Text].
5. Canepari, P., M. Boaretti, M. del Mar Lleó, and G. Satta. 1990. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. 34:1220-1226[Abstract/Free Full Text].
6. Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791[Abstract].
7. Chatterjee, A. N. 1969. Use of bacteriophage-resistant mutants to study the nature of the bacteriophage receptor site of Staphylococcus aureus. J. Bacteriol. 98:519-527[Abstract/Free Full Text].
8. de Lencastre, H., A. M. Sà Figueiredo, C. Urban, J. Rahal, and A. Tomasz. 1991. Multiple mechanisms of methicillin resistance and improved methods for detection in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 35:632-639[Abstract/Free Full Text].
9. Eliopoulous, G. M., C. Thauvin, B. Gerson, and R. C. Moellering. 1985. In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 27:357-362[Abstract/Free Full Text].
10. Finney, D. J. 1971. Probit analysis, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
11. Flandrois, J. P., G. Carret, C. Pichat, and M. Peyret. 1988. Mise en évidence d'un effet inoculum sur l'estimation de la concentration minimale inhibitrice du LY 146032. Pathol. Biol. 36:377-380[Medline]. (Summary in English.)
12. Hanberger, H., L. E. Nilsson, R. Maller, and B. Isaksson. 1991. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. 35:1710-1716[Abstract/Free Full Text].
13. Hartman, B. J., and A. Tomasz. 1986. Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 29:85-92[Abstract/Free Full Text].
14. Howe, R. A., M. Wootton, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 1999. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 44:675-678[Abstract/Free Full Text].
15. Jolliffe, L. K., R. J. Doyle, and U. N. Streips. 1981. The energized membrane and cellular autolysis in Bacillus subtilis. Cell 25:753-763[CrossRef][Medline].
16. Kaatz, G. W., S. M. Seo, V. N. Reddy, E. M. Bailey, and M. J. Rybak. 1990. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:2081-2085[Abstract/Free Full Text].
17. Kashket, E. R., A. G. Blanchard, and W. C. Metzger. 1980. Proton motive force during growth of Streptococcus lactis cells. J. Bacteriol. 143:128-134[Abstract/Free Full Text].
18. Liebowitz, L. D., J. Saunders, L. J. Chalkley, and H. J. Koornhof. 1988. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob. Agents Chemother. 32:24-26[Abstract/Free Full Text].
19. Louie, A., A. L. Baltch, W. J. Ritz, R. P. Smith, and M. Asperilla. 1993. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy 39:302-310[Medline].
20. Mates, S. M., L. Patel, H. R. Kaback, and M. H. Miller. 1983. Membrane potential in anaerobically growing Staphylococcus aureus and its relationship to gentamicin uptake. Antimicrob. Agents Chemother. 23:526-530[Abstract/Free Full Text].
21. Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
22. Mouton, R. P., and S. L. T. M. Mulders. 1987. LY146032: activity and resistance development in vitro. J. Antimicrob. Chemother. 20:513-517[Abstract/Free Full Text].
23. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Rottenberg, H. 1979. The measurement of membrane potential and Delta pH in cells, organelles, and vesicles. Methods Enzymol. 55:547-569[Medline].
25. Rybak, M. J, E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066[Abstract/Free Full Text].
26. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450[Abstract/Free Full Text].
27. Steinberg, D. A., M. A. Hurst, C. A. Fujii, A. H. C. Kung, J. F. Ho, F.-C. Cheng, D. J. Loury, and J. C. Fiddes. 1997. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob. Agents Chemother. 41:1738-1742[Abstract].
28. Tally, F. P., M. Zeckel, M. M. Wasilewski, C. Carini, C. L. Berman, G. L. Drusano, and F. B. Oleson, Jr. 1999. Daptomycin: a novel agent for Gram-positive infections. Exp. Opin. Investig. Drugs 8:1223-1238.
29. Wale, M. C. J., L. J. Wale, and D. Greenwood. 1988. Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin. Eur. J. Clin. Microbiol. Infect. Dis. 7:809-812[CrossRef][Medline].

Antimicrobial Agents and Chemotherapy, June 2001, p. 1799-1802, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1799-1802.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Murillo, O., Garrigos, C., Pachon, M. E., Euba, G., Verdaguer, R., Cabellos, C., Cabo, J., Gudiol, F., Ariza, J. (2009). Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4252-4257 [Abstract] [Full Text]  
  • Mishra, N. N., Yang, S.-J., Sawa, A., Rubio, A., Nast, C. C., Yeaman, M. R., Bayer, A. S. (2009). Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2312-2318 [Abstract] [Full Text]  
  • Hachmann, A.-B., Angert, E. R., Helmann, J. D. (2009). Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Antimicrob. Agents Chemother. 53: 1598-1609 [Abstract] [Full Text]  
  • Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K. (2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother. 52: 4289-4299 [Abstract] [Full Text]  
  • Hobbs, J. K., Miller, K., O'Neill, A. J., Chopra, I. (2008). Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62: 1003-1008 [Abstract] [Full Text]  
  • Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V., Osborn, M. K. (2008). Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 61: 1394-1396 [Full Text]  
  • Quinn, B., Hussain, S., Malik, M., Drlica, K., Zhao, X. (2007). Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383 [Abstract] [Full Text]  
  • Goldstein, B. P., Draghi, D. C., Sheehan, D. J., Hogan, P., Sahm, D. F. (2007). Bactericidal Activity and Resistance Development Profiling of Dalbavancin. Antimicrob. Agents Chemother. 51: 1150-1154 [Abstract] [Full Text]  
  • Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M. (2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208-1214 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Wootton, M., MacGowan, A. P., Walsh, T. R. (2006). Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates. Antimicrob. Agents Chemother. 50: 4195-4197 [Abstract] [Full Text]  
  • Diederen, B. M. W., van Duijn, I., Willemse, P., Kluytmans, J. A. J. W. (2006). In Vitro Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus, Including Heterogeneously Glycopeptide-Resistant Strains.. Antimicrob. Agents Chemother. 50: 3189-3191 [Abstract] [Full Text]  
  • Jevitt, L. A., Thorne, G. M., Traczewski, M. M., Jones, R. N., McGowan, J. E. Jr., Tenover, F. C., Brown, S. D. (2006). Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates.. J. Clin. Microbiol. 44: 3098-3104 [Abstract] [Full Text]  
  • Green, M. R, Anasetti, C., Sandin, R. L, Rolfe, N. E, Greene, J. N (2006). Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 12: 179-181 [Abstract]  
  • Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R., Vanhoof, R., De Mendonca, R., Struelens, M. J. (2006). In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals.. Antimicrob. Agents Chemother. 50: 2680-2685 [Abstract] [Full Text]  
  • Tyrrell, K. L., Citron, D. M., Warren, Y. A., Fernandez, H. T., Merriam, C. V., Goldstein, E. J. C. (2006). In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.. Antimicrob. Agents Chemother. 50: 2728-2731 [Abstract] [Full Text]  
  • Friedman, L., Alder, J. D., Silverman, J. A. (2006). Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2137-2145 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A. (2006). Assessment of Two Commercial Susceptibility Test Methods for Determination of Daptomycin MICs.. J. Clin. Microbiol. 44: 2126-2129 [Abstract] [Full Text]  
  • Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C. Jr., Eliopoulos, G. M. (2006). Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin.. Antimicrob. Agents Chemother. 50: 1581-1585 [Abstract] [Full Text]  
  • Marty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., Pillai, S. K. (2006). Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. J. Clin. Microbiol. 44: 595-597 [Abstract] [Full Text]  
  • Skiest, D. J. (2006). Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin. J. Clin. Microbiol. 44: 655-656 [Abstract] [Full Text]  
  • Lesho, E. P., Wortmann, G. W., Craft, D., Moran, K. A. (2006). De Novo Daptomycin Nonsusceptibility in a Clinical Isolate. J. Clin. Microbiol. 44: 673-673 [Full Text]  
  • Bogdanovich, T., Ednie, L. M., Shapiro, S., Appelbaum, P. C. (2005). Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 4210-4219 [Abstract] [Full Text]  
  • Hayden, M. K., Rezai, K., Hayes, R. A., Lolans, K., Quinn, J. P., Weinstein, R. A. (2005). Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus. J. Clin. Microbiol. 43: 5285-5287 [Abstract] [Full Text]  
  • Long, J. K., Choueiri, T. K., Hall, G. S., Avery, R. K., Sekeres, M. A. (2005). Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia. Mayo Clin Proc. 80: 1215-1216 [Abstract]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Miao, V., Coeffet-LeGal, M.-F., Brian, P., Brost, R., Penn, J., Whiting, A., Martin, S., Ford, R., Parr, I., Bouchard, M., Silva, C. J., Wrigley, S. K., Baltz, R. H. (2005). Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151: 1507-1523 [Abstract] [Full Text]  
  • Steenbergen, J. N., Alder, J., Thorne, G. M., Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55: 283-288 [Abstract] [Full Text]  
  • Lai, J.-J., Brodeur, S. K (2004). Physical and Chemical Compatibility of Daptomycin with Nine Medications. The Annals of Pharmacotherapy 38: 1612-1616 [Abstract] [Full Text]  
  • Dvorchik, B., Arbeit, R. D., Chung, J., Liu, S., Knebel, W., Kastrissios, H. (2004). Population Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 48: 2799-2807 [Abstract] [Full Text]  
  • Dvorchik, B. (2004). Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics. J Clin Pharmacol 44: 715-722 [Abstract] [Full Text]  
  • Alder, J., Li, T., Yu, D., Morton, L., Silverman, J., Zhang, X.-X., Critchley, I., Thorne, G. (2003). Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection. Antimicrob. Agents Chemother. 47: 3561-3566 [Abstract] [Full Text]  
  • Silverman, J. A., Perlmutter, N. G., Shapiro, H. M. (2003). Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 2538-2544 [Abstract] [Full Text]  
  • Laganas, V., Alder, J., Silverman, J. A. (2003). In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid Biosynthesis. Antimicrob. Agents Chemother. 47: 2682-2684 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  
  • Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Thornsberry, C., Sahm, D. F., Karlowsky, J. A. (2003). Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 47: 1689-1693 [Abstract] [Full Text]  
  • Sakoulas, G., Eliopoulos, G. M., Alder, J., Eliopoulos, C. T. (2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus. Antimicrob. Agents Chemother. 47: 1714-1718 [Abstract] [Full Text]  
  • Critchley, I. A., Draghi, D. C., Sahm, D. F., Thornsberry, C., Jones, M. E., Karlowsky, J. A. (2003). Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51: 639-649 [Abstract] [Full Text]  
  • Oliva, B., Miller, K., Caggiano, N., O'Neill, A. J., Cuny, G. D., Hoemann, M. Z., Hauske, J. R., Chopra, I. (2003). Biological Properties of Novel Antistaphylococcal Quinoline-Indole Agents. Antimicrob. Agents Chemother. 47: 458-466 [Abstract] [Full Text]  
  • Kaatz, G. W., Moudgal, V. V., Seo, S. M., Kristiansen, J. E. (2003). Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 719-726 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2003). In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates. Antimicrob. Agents Chemother. 47: 337-341 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»